ASJC Scopus subject areas
Access to Document
The risk of respiratory tract infections in patients with psoriasis treated with interleukin 23 pathway–inhibiting biologics : A meta-estimate of pivotal trials relevant to decision making during the COVID-19 pandemic. / Syed, Maha N.; Shin, Daniel B.; Wan, Marilyn T.; Winthrop, Kevin L.; Gelfand, Joel M.In: Journal of the American Academy of Dermatology, Vol. 83, No. 5, 11.2020, p. 1523-1526.
Research output: Contribution to journal › Article
TY - JOUR
T1 - The risk of respiratory tract infections in patients with psoriasis treated with interleukin 23 pathway–inhibiting biologics
T2 - A meta-estimate of pivotal trials relevant to decision making during the COVID-19 pandemic
AU - Syed, Maha N.
AU - Shin, Daniel B.
AU - Wan, Marilyn T.
AU - Winthrop, Kevin L.
AU - Gelfand, Joel M.
N1 - Funding Information: Funding sources: Supported in part by a grant (P30AR069589-03) from the National Institutes of Health (to Dr Gelfand).Disclosure: Drs Syed and Wan are supported in part by a grant from Pfizer. Dr Winthrop receives grants from Bristol Myers Squibb and Pfizer and is a consultant for UCB, AbbVie, Lilly, Bristol Myers Squibb, Pfizer, GlaxoSmithKline, and Roche. Dr Gelfand served as a consultant for Bristol Myers Squibb, Boehringer Ingelheim, GlaxoSmithKline, Janssen Biologics, Novartis Corp, Regeneron, UCB (data safety and monitoring board), Sanofi, Pfizer Inc, receiving honoraria; receives research grants (to the Trustees of the University of Pennsylvania) from AbbVie, Janssen, Novartis Corp, Sanofi, Celgene, Ortho Dermatologics, and Pfizer Inc; has received payment for continuing medical education work related to psoriasis that was supported indirectly by Eli Lilly and Company and Ortho Dermatologics; is a copatent holder of resiquimod for the treatment of cutaneous T-cell lymphoma; and is a deputy editor for the Journal of Investigative Dermatology, receiving honoraria from the Society for Investigative Dermatology. Dr Shin has no conflicts of interest to declare.
PY - 2020
Y1 - 2020
UR - http://www.scopus.com/inward/record.url?scp=85090990531&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85090990531&partnerID=8YFLogxK
U2 - 10.1016/j.jaad.2020.06.1014
DO - 10.1016/j.jaad.2020.06.1014
M3 - Article
C2 - 32622891
AN - SCOPUS:85090990531
VL - 83
SP - 1523
EP - 1526
JO - Journal of the American Academy of Dermatology
JF - Journal of the American Academy of Dermatology
SN - 0190-9622
IS - 5